Patent 08394390 - Neisserial antigenic peptides > Claims
- 1. An isolated polypeptide having the amino acid sequence of SEQ ID NO: 35971.
- 2. The isolated polypeptide of claim 1, wherein the polypeptide does not comprise the full length protein sequence of SEQ ID NO: 41367.
- 7. A composition comprising the isolated polypeptide of claim 2 with a pharmaceutically acceptable carrier.
- 8. The composition of claim 7 further comprising aluminum phosphate.
- 7. A composition comprising the isolated polypeptide of claim 2 with a pharmaceutically acceptable carrier.
- 3. The isolated polypeptide of claim 1, wherein the amino acid sequence of SEQ ID NO: 35971 is an antigenic fragment of SEQ ID NO: 41367.
- 4. The isolated polypeptide of claim 3, wherein the polypeptide does not comprise the full length protein sequence of SEQ ID NO: 41367.
- 11. A composition comprising the isolated polypeptide of claim 4 with a pharmaceutically acceptable carrier.
- 12. The composition of claim 11 further comprising aluminum phosphate.
- 11. A composition comprising the isolated polypeptide of claim 4 with a pharmaceutically acceptable carrier.
- 9. A composition comprising the isolated polypeptide of claim 3 with a pharmaceutically acceptable carrier.
- 10. The composition of claim 9 further comprising aluminum phosphate.
- 4. The isolated polypeptide of claim 3, wherein the polypeptide does not comprise the full length protein sequence of SEQ ID NO: 41367.
- 5. A composition comprising the isolated polypeptide of claim 1 with a pharmaceutically acceptable carrier.
- 6. The composition of claim 5 further comprising aluminum phosphate.
- 2. The isolated polypeptide of claim 1, wherein the polypeptide does not comprise the full length protein sequence of SEQ ID NO: 41367.
- 13. A purified polypeptide having the amino acid sequence of SEQ ID NO: 35971.
- 14. The purified polypeptide of claim 13, wherein the polypeptide does not comprise the full length protein sequence of SEQ ID NO: 41367.
- 19. A composition comprising the purified polypeptide of claim 14 with a pharmaceutically acceptable carrier.
- 20. The composition of claim 19 further comprising aluminum phosphate.
- 19. A composition comprising the purified polypeptide of claim 14 with a pharmaceutically acceptable carrier.
- 15. The purified polypeptide of claim 13, wherein the amino acid sequence of SEQ ID NO: 35971 is an antigenic fragment of SEQ ID NO: 41367.
- 16. The purified polypeptide of claim 15, wherein the polypeptide does not comprise the full length protein sequence of SEQ ID NO: 41367.
- 23. A composition comprising the purified polypeptide of claim 16 with a pharmaceutically acceptable carrier.
- 24. The composition of claim 23 further comprising aluminum phosphate.
- 23. A composition comprising the purified polypeptide of claim 16 with a pharmaceutically acceptable carrier.
- 21. A composition comprising the purified polypeptide of claim 15 with a pharmaceutically acceptable carrier.
- 22. The composition of claim 21 further comprising aluminum phosphate.
- 16. The purified polypeptide of claim 15, wherein the polypeptide does not comprise the full length protein sequence of SEQ ID NO: 41367.
- 17. A composition comprising the purified polypeptide of claim 13 with a pharmaceutically acceptable carrier.
- 18. The composition of claim 17 further comprising aluminum phosphate.
- 14. The purified polypeptide of claim 13, wherein the polypeptide does not comprise the full length protein sequence of SEQ ID NO: 41367.